The Central Drugs Standard Control Organisation is launching a registration framework for pharmaceutical packaging suppliers to curb drug counterfeiting. This move aims to fix gaps in supply chain traceability after instances where genuine packaging was misused for fake medicines.
New Rules For Packaging Suppliers
The Central Drugs Standard Control Organisation (CDSCO) is preparing to introduce a formal registration system for manufacturers and suppliers of printed pharmaceutical packaging materials. Under the upcoming framework, these entities will need to obtain a specific 'packaging registration certificate' through a government portal. Each supplier will be issued a unique registration number, which must be printed on all packaging materials. This requirement is designed to provide regulators and drug makers with a clear path to trace any box, label, or strip back to its original manufacturer.
Why The Move Was Necessary
The decision follows concerns over the misuse of legitimate packaging materials. Investigations into counterfeit drugs, including cases involving weight-loss medications like Semaglutide and rabies vaccines, revealed that the packaging itself was often genuine. In many instances, these materials were manufactured in India, exported, and then diverted by third parties to house and sell counterfeit drugs abroad. By formalizing the production and distribution of this packaging, regulators aim to close a significant loophole that allows rogue actors to profit by using authentic-looking packaging for fake medical products.
Regulatory Shift For The Sector
Currently, packaging suppliers operate largely outside the direct scope of the Drugs and Cosmetics Act, 1940. Their quality and standards have traditionally been managed through vendor qualification and supplier management systems implemented by licensed drug companies, as outlined in Schedule M of the Drugs Rules, 1945. This new mandate will bring packaging material production directly under the regulator's purview. For businesses in the packaging sector, this transition marks a shift toward higher compliance standards. Firms will need to align their operations with new government guidelines to maintain their ability to supply the pharmaceutical industry.
What Investors Should Monitor
The primary focus for investors will be the implementation timeline and the operational impact of these new compliance standards. Companies that supply packaging to large pharmaceutical players may face increased audit requirements and administrative processes as they work to obtain their unique registration numbers. Investors may want to track the official guidelines and deadlines released by the CDSCO, as these will clarify the cost and time required for compliance. Additionally, companies with strong existing quality and supplier management systems may find the transition easier, while those relying on fragmented supply chains could face more complex hurdles to ensure every piece of packaging is traceable as mandated.